Pituitary block with gonadotrophin-releasing hormone antagonist during intrauterine insemination cycles: a systematic review and meta-analysis of randomised controlled trials by Vitagliano, A et al.
Pituitary block with gonadotrophin-releasing
hormone antagonist during intrauterine
insemination cycles: a systematic review and
meta-analysis of randomised controlled trials
A Vitagliano,a G Saccone,b M Noventa,a A Borini,c ME Coccia,d GB Nardelli,a C Saccardi,a
G Bifulco,b PS Litta,a A Andrisania
a Department of Women and Children’s Health, Unit of Gynaecology and Obstetrics, University of Padua, Padua, Italy b Department of
Neuroscience Reproductive Sciences and Dentistry, School of Medicine, University of Naples Federico II, Naples, Italy c 9.Baby, Family and
Fertility Centre Bologna, Bologna, Italy d Department of Biomedical, Experimental and Clinical Sciences, Division of Obstetrics and
Gynaecology, Careggi University Hospital, University of Florence, Florence, Italy
Correspondence: A Vitagliano, Department of Women and Children’s Health, Unit of Gynaecology and Obstetrics, University of Padua,
Via Giustiniani 3, Padua, Italy. Email: amerigovitagliano.md@gmail.com
Accepted 2 April 2018. Published Online 4 June 2018.
This article includes Author Insights, a video abstract available at https://vimeo.com/rcog/authorinsights15269
Background Several randomised controlled trials (RCTs) have
investigated the usefulness of pituitary block with gonadotrophin-
releasing hormone (GnRH) antagonists during intrauterine
insemination (IUI) cycles, with conflicting results.
Objective The aim of the present systematic review and meta-analysis
of RCTs was to evaluate the effectiveness of GnRH antagonist
administration as an intervention to improve the success of IUI cycles.
Search strategy Electronic databases (MEDLINE, Scopus,
EMBASE, Sciencedirect) and clinical registers were searched from
their inception until October 2017.
Selection criteria Randomised controlled trials of infertile women
undergoing one or more IUI stimulated cycles with GnRH
antagonists compared with a control group.
Data collection and analysis The primary outcomes were ongoing
pregnancy/live birth rate (OPR/LBR) and clinical pregnancy rate
(CPR). Pooled results were expressed as odds ratio (OR) or mean
differences with 95% confidence interval (95% CI). Sources of
heterogeneity were investigated through sensitivity and subgroups
analysis. The body of evidence was rated using GRADE methodology.
Publication bias was assessed with funnel plot, Begg’s and Egger’s tests.
Main results Fifteen RCTs were included (3253 IUI cycles, 2345
participants). No differences in OPR/LBR (OR 1.14, 95% CI 0.82–
1.57, P = 0.44) and CPR (OR 1.28, 95% CI 0.97–1.69, P = 0.08)
were found. Sensitivity and subgroup analyses did not provide
statistical changes in pooled results. The body of evidence was
rated as low (GRADE 2/4). No publication bias was detected.
Conclusion Pituitary block with GnRH antagonists does not
improve OPR/LBR and CPR in women undergoing IUI cycles.
Keywords Clinical pregnancy, gonadotrophin-releasing hormone
antagonists, intrauterine insemination, ongoing pregnancy,
premature luteinisation.
Tweetable abstract Pituitary block with GnRH antagonists does
not improve the success of IUI cycles.
Please cite this paper as: Vitagliano A, Saccone G, Noventa M, Borini A, Coccia ME, Nardelli GB, Saccardi C, Bifulco G, Litta PS, Andrisani A.
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Introduction
Intrauterine insemination (IUI) with controlled ovarian stimu-
lation is the treatment of first choice for subfertile couples due
to low costs, minimal invasiveness and requirement of minimal
clinical surveillance.1–3 The rationale is to increase the natural
chances of conceiving by obtaining two or three dominant folli-
cles and performing IUI after multiple ovulation triggering.4
Different strategies have been proposed to improve the
outcome of IUI-stimulated cycles, including endometrial
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Systematic review
scratching,5 various ovarian stimulation protocols6,7 and
pituitary block with gonadotrophin-releasing hormone
(GnRH) antagonists (GnRH-ant).4
These antagonists are synthetic analogues of GnRH that
exert a competitive block of GnRH receptors in the ante-
rior pituitary gland.8–10 The introduction of GnRH-ant
during IUI-stimulated cycles may prevent spontaneous
ovulation and premature luteinisation, and may improve
clinical pregnancy rate.11,12 However, since their first use in
2001,13 the effectiveness of this strategy remains a subject
of debate.
Hence, the aim of the present systematic review was to
evaluate the effects of GnRH-ant administration in women
undergoing IUI-stimulated cycles.
Methods
Study design
This is a systematic review and meta-analysis of ran-
domised controlled trials (RCTs) evaluating the effective-
ness of GnRH-ant use in IUI cycles. The study protocol
was registered in PROSPERO before the start of the litera-
ture search (CRD42017081201). The review was written fol-
lowing the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) guidelines.14
Search strategy
Electronic databases (Medline, Scopus, Embase, Sciencedi-
rect, the Cochrane library, Clinicaltrials.gov, Cochrane Cen-
tral Register of Controlled Trials, EU Clinical Trials
Register and World Health Organization International
Clinical Trials Registry Platform) were searched from their
inception until October 2017.
Key search terms were the following text words: gonado-
trophin-releasing hormone antagonists OR gonadotrophin-
releasing hormone analogues OR GnRH antagonists OR
cetrorelix OR ganirelix [Mesh/Emtree] AND insemination
OR IUI.
Inclusion criteria
 Language: Studies reported in English language
 Study designs: Randomised controlled trials
 Population: Infertile women undergoing one or more
IUI-stimulated cycles
 Intervention: GnRH-ant administration
 Timing of intervention: During the course of ovarian
stimulation
 Comparator: Infertile women undergoing IUI-stimulated
cycles not receiving GnRH-ant
Outcomes:
 Primary outcomes: Ongoing pregnancy/live birth rate,
clinical pregnancy rate
 Secondary outcomes: Miscarriage rate, multiple preg-
nancies, premature luteinisation, premature luteinising
hormone (LH) rise, preovulatory follicles, endometrial
thickness, total dose of gonadotrophins, ovarian hyper-
stimulation syndrome, cancelled cycles, spontaneous
ovulation
 Outcomes definitions:
o Ongoing pregnancy (per cycle [OPR/LBR]): ‘Ongoing
pregnancy’ defined as a pregnancy beyond 12 weeks
of gestation
o Live birth (per cycle [OPR/LBR]): ‘Live birth’ defined as
the delivery of one or more living and viable infants
o Clinical pregnancy rate (per cycle [CPR]): Defined as
the presence of a gestational sac on transvaginal ultra-
sound or other definitive clinical signs
o Multiple pregnancies (per cycle): Defined as the presence
of more than one gestational sac on transvaginal ultra-
sound
o Miscarriage rate (per clinical pregnancy): Defined as
fetal loss before the 20th week of gestation
o Premature luteinisation (per cycle): Serum rise of pro-
gesterone ≥ 2 ng/mL before ovulation induction with/
without concomitant LH elevation (≥ 10–15 IU/l)
o Premature LH surge (per cycle): As defined by original tri-
als (serum LH ≥ 10–15 mIU/ml before ovulation induc-
tion)
o Preovulatory follicles (per cycle): Number of follicles
≥ 16 mm (at transvaginal ultrasound) on the day of
ovulation induction
o Endometrial thickness (per cycle): Maximum anterior–
posterior thickness of the endometrial echo (mm) on
the day of ovulation induction (on transvaginal ultra-
sound)
o Total gonadotrophin dose (per cycle): The total amount
of gonadotrophins administered before ovulation
induction
o Cancelled cycles: Cycles cancelled due to inadequate
ovarian response (poor/excessive)
o Spontaneous ovulation (per cycle): Cycles cancelled due
to spontaneous ovulation
o Ovarian hyperstimulation syndrome (per cycle [OHSS]):
defined as the occurrence of moderate or severe OHSS
before or after IUI.
Study selection and data extraction
Titles and abstracts were independently screened by two
authors (AV, GS). The same authors independently
assessed studies for inclusion and extracted data about
study features (design, country and time of the study),
populations (participant number and characteristics), type
of intervention, ovarian stimulation cycles (drugs, timing
of ovulation induction) and IUI outcomes. A manual
search of references of included studies was also performed
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to avoid missing relevant data. The results were compared,
and any disagreement was resolved by consensus.
Risk of bias
Two authors (AV, MN) independently assessed the method-
ological quality of included studies by using the criteria out-
lined in the Cochrane Handbook for Systematic Reviews of
Interventions. Seven specific domains related to risk of bias
were assessed: random sequence generation; allocation con-
cealment; blinding of participants and personnel; blinding of
outcome assessment; incomplete outcome data; selective data
reporting; other bias. Authors’ judgements were expressed as
‘low risk’, ‘high risk’ or ‘unclear risk’ of bias. For the estima-
tion of ‘selective data reporting’, we evaluated study proto-
cols, when available. If not available, studies were judged at
unclear risk of bias. Results were compared and disagree-
ments were resolved by consensus.
Statistical analysis
Data analysis was performed by two authors (AV, GS)
using REVIEW MANAGER Version 5.3 (The Cochrane Collabo-
ration, Software Update, Oxford, UK). All analyses were
carried out with an intention-to-treat approach (number of
events per woman randomised), using the random effects
model of DerSimonian and Laird (assuming that the data
being analysed were drawn from a hierarchy of different
populations). Dichotomous variables were analysed using
the odds ratio (OR) with a 95% CI. Continuous variables
were compared using the means and standard deviations of
outcome measures and expressed as mean differences
(MD) among groups (95% CI). Significance level was set at
P < 0.05. Heterogeneity was measured using I-squared
(Higgins I2). A subgroup analysis was also performed to
evaluate the specific influence of different interventions
(cetrorelix, ganirelix), intervention schemes (fixed, flexible)
and populations [polycystic ovarian syndrome (PCOS),
non-PCOS] on pooled results. In addition, we performed a
sensitivity analysis by serially excluding each study and dif-
ferent study subgroups (according to the methodological
quality judgement) from the pooled analysis.
Publication bias was assessed (for the primary outcomes)
with the use of funnel plot (when at least ten studies were
included in data analysis, according to Cochrane Handbook
Recommendations) and statistically by using Begg’s and
Egger’s tests.
Grading of evidence
Two authors (AV and MN) independently evaluated the
quality of evidence for the primary outcomes using GRADE
(Grading of Recommendations Assessment Development
and Evaluation working group) methodology.15 The
GRADE criteria allow the assessment of a body of evidence
on the basis of study design, risk of bias, indirectness,
inconsistency, imprecision, large effect size, plausible con-
founding, dose–response gradient and publication bias.
Dose–response gradient was not evaluated because the
intervention had standard dose. Disagreements between
reviewers were resolved by consensus.
Results
Study selection
In all, 23 studies were assessed for eligibility. Eight studies were
subsequently excluded after the examination of full-text: two
studies were not RCT.16,17 Ragni et al.13 aimed to evaluate the
luteal phase profile in women undergoing IUI-stimulated
cycles with/without GnRH-ant. Two studies evaluated the
effectiveness of different stimulation protocols in women
receiving gonadotrophins plus GnRH-ant before IUI.18,19 Two
additional studies investigated the benefits of GnRH-ant use
to avoid IUI on weekends.20,21 In Nada et al.,22 the interven-
tion (GnRH-ant) group and control (GnRH-ant-free) group
received different stimulation drugs (respectively gonadotro-
pins and clomiphene citrate). Finally, 15 trials4,11,12,23–34 were
included in the meta-analysis (Figure S1).
Included studies
The 15 trials included 3253 IUI cycles and 2345 participants.
A total of 1610 IUI cycles were assigned to the intervention
group and 1643 to the control group. One study34 involved
three study groups, of which two received the intervention
with different timing. Two were placebo-controlled trials.4,30
Study characteristics are summarised in the (Table S1).
Participants
The majority of the trials included women with unex-
plained infertility, mild endometriosis (stage I–II) and nor-
mal semen analysis/mild male factor. Two studies12,25
included also women with PCOS, and two additional stud-
ies29,34 involved only women with PCOS.
In seven studies4,23–28 participants had no history of previ-
ous assisted reproductive treatments, in one study29 women
had three or more previous IUI failures and in another study30
women had no more than three previous IUI failures. In two
studies women had history of one34 or two31 previous ovarian
stimulation cycles with clomiphene citrate. In the remaining
studies11,12,32,33 previous assisted reproductive treatments
attempts were not specified.
IUI cycles
In nine trials,11,12,23,25–27,30,31,33 women underwent a single
IUI-stimulated cycle, whereas in other studies they under-
went up to three4,29,34 or four24,28,32 cycles.
Most studies used recombinant follicle-stimulating hor-
mone daily (50–150 IU starting dose) for ovarian stimula-
tion, starting from day 2–4, whereas Kamath et al.12
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administered human menopausal gonadotrophin 75 IU
daily (from day 3). Two other studies used the combina-
tion of letrozole (5 mg daily from day 3 to 7) plus recom-
binant follicle-stimulating hormone (150 UI on days 4, 6, 8
and then daily until ovulation induction)33 or clomiphene
citrate (100 mg daily from day 3 to 7) plus human meno-
pausal gonadotrophin (75/150 UI from day 8).23
Ovulation induction was triggered with 5000–10 000 UI
of urinary human chorionic gonadotrophin (hCG) in most
studies, except for four4,25,29,33,34 (which used recombinant
hCG, 250 lg). Recombinant/urinary hCG was administered
when at least one follicle (but no more than three) was
≥ 17–20 mm (in mean diameter) at transvaginal ultrasound
scan. A single IUI (30–48 hours later) or double IUI (20
and 34 hours32 or 12 and 36 hours25 after hCG trigger)
was subsequently performed. In nine studies, IUI was fol-
lowed by luteal phase support with vaginal progesterone
(50–800 mg/day), whereas in the remaining studies4,27,29 it
was not administered or not reported.28,31,33
Intervention
Pituitary block was performed with ganirelix11,26–30,34
(0.25 mg daily) or cetrorelix4,12,23–25,31–33 (0.25 mg daily)
with a flexible scheme (except for Williams et al.28 and one
group in the study by Stadtmauer et al.,34 where GnRH-ant
was started respectively on day 1 or 6 of ovarian stimula-
tion). GnRH-ant was started when at least one follicle
≥ 13 mm,25,27,34 14 mm,4,12,29–33 15 mm24 or 16 mm11,23,26
in mean diameter was observed at transvaginal ultrasound
scan and continued until ovulation induction.
Assessment of the risk of study BIAS
Random sequence generation: All studies but one24 used
adequate method of random sequence generation (com-
puter randomisation or random number tables).
Allocation concealment: Seven studies11,23–26,29–31 did not
provide information about the method of allocation, so
were judged at unclear risk of bias. Remaining studies were
at low risk of bias.
Blinding of participants and personnel: All studies but
two4,30 were not blinded for participants and personnel, so
were judged at high risk of bias.
Blinding of outcome assessment: Three studies4,28,30 were
assessor-blinded, the remaining were at high risk of bias.
Incomplete outcome data: All studies but four23,25,31,33 were
judged at low risk of bias. Two studies25,33 were judged at
unclear risk of bias as the missing data were not about pri-
mary outcomes, while two other studies23,31 were considered
at high risk of bias due to missing relevant data about pri-
mary outcomes.
Selective data reporting: All studies were judged at unclear
risk of selective data reporting due to absence of recorded
study protocol, except for the study by Cantineau et al.4
Other bias: Three studies23,24,31 were judged at high risk of
other bias due to missing information about study
methodology and/or patient characteristics. Lambalk
et al.30 was judged at unclear risk of bias because luteal
phase support was variable according to preference of clini-
cians. Another study25 was judged at unclear risk of bias
because it was published as a short communication (Fig-
ure S2).
Effects of intervention
Primary outcomes
Analysis of 1964 IUI cycles from seven studies4,11,27,29,30,34 did
not show any difference in OPR/LBR between groups (OR
1.14, 95% CI 0.82–1.57, I2 = 31%, P = 0.44) (Figure 1A).
Similarly, the analysis of 3192 IUI cycles did not show any
advantage from GnRH-ant in terms of CPR (OR 1.28, 95%
CI 0.97–1.69, I2 = 39%, P = 0.08) (Figure 1B and Video S1).
Secondary outcomes
Significantly lower risks of premature luteinisation (OR
4.39, 95% CI 2.73–7.05, I2 = 0%, P > 0.00001) (Figure 2A)
and premature LH rise (OR 3.98, 95% CI 2.53–6.26,
I2 = 28%) (Figure 2B) were observed in women receiving
intervention, in addition to lower cycle cancellation due to
spontaneous ovulation (OR 2.40, 95% CI 1.12–5.15,
I2 = 1%). In contrast, endometrial thickness was found to
be lower in the GnRH-ant group in comparison to controls
(MD = –0.39; 95% CI –0.70 to –0.08], I2 = 40%).
No difference was observed in terms of miscarriage
rate (OR 1.11, 95% CI 0.65–1.89, I2 = 0%, P = 0.71),
multiple pregnancies (OR 1.49, 95% CI 0.82–2.70,
I2 = 0%), preovulatory follicles (MD = –0.07; 95% CI –
0.34 to 0.48, I2 = 97%) and total gonadotrophin dose
(MD = –26.51; 95% CI –22.85 to 75.86, I2 = 84%)
among groups. Similarly, no substantial difference in
OHSS risk and cancelled cycles due to poor response/hy-
per-response was observed.
Subgroup analysis and sensitivity analysis
Subgroup analysis according to type of intervention
(cetrorelix versus ganirelix), intervention scheme (fixed ver-
sus flexible) and type of patients (PCOS versus non-PCOS)
showed no statistical difference among subgroups (Fig-
ure 1A,B).
The serial exclusion of each study or specific study sub-
groups according to authors’ quality judgement (studies at
low risk of bias in at least four domains) did not provide
substantial changes to pooled results.
Publication bias and quality of evidence
No publication bias was found for the outcome OPR/LBR
(Begg’s test: P = 0.05; Egger’s test: P = 0.07). Similarly, the
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Figure 1. Gonadotrophin-releasing hormone antagonist effects on ongoing pregnancy/live birth rate (A), and clinical pregnancy rate (B).
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visual inspection of funnel plot, Begg’s (P = 0.50) and
Egger’s test (P = 0.82) did not show the presence of publi-
cation BIAS for the outcome CPR (Figure S3).
The quality of evidence for OPR/LBR and CPR was
judged as low due to concerns about the overall method-
ological quality of included studies, moderate inconsistency
and small number of events included (Table 1).
Discussion
In spite of recent insights about endometrial-factor infer-
tility,35–37 the introduction of novel targeted drugs38–40
and individualised ovarian stimulation protocols,41,42 the
success rate of IUI is still suboptimal.12,43,44 Recently,
several RCTs have investigated the effectiveness of pitu-
itary block with GnRH-ant during controlled ovarian
stimulation and IUI, with controversial results. Our study
goal was to summarise the available evidence on this
topic.
Main findings
The present meta-analysis, from 15 RCTs, included a total
number of 3253 IUI cycles and 2345 women. We found
that GnRH-ant use did not improve OPR/LBR and CPR
in women undergoing IUI stimulated cycles (P = ns).
Nevertheless, GnRH-ant were effective in reducing the risk
Figure 2. Gonadotrophin-releasing hormone antagonist effects on premature luteinisation (A), and premature luteinising hormone rise (B).
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of premature luteinisation (P > 0.00001), premature LH
rise (P > 0.00001) and spontaneous ovulation (P = 0.02).
In contrast, GnRH-ant use correlated with lower endome-
trial thickness values at the time of ovulation induction
(P = 0.02). No difference was observed in terms of mis-
carriage rate, multiple pregnancies, preovulatory follicles,
total gonadotrophin dose, OHSS and cancelled cycles due
to hypo-/hyper-response between groups.
A review by Luo et al.45 investigated the effects of GnRH-
ant on IUI outcomes. The authors found that GnRH-ant
were effective in improving CPR and reducing the risk of
premature luteinisation, but they did not evaluate the other
outcomes included in the present review (i.e. ongoing preg-
nancy/live birth rate). Moreover, since the study by Luo
et al., new RCTs23,24,31 have been published.
Strengths and limitations
The present meta-analysis, to our knowledge, is the largest
and most comprehensive on this issue. Strict inclusion cri-
teria and rigorous methodology represent further points of
strength of our study. In addition, sensitivity and subgroup
analyses did not produce statistical changes to our results,
confirming their consistency.
The main limitations of our study are inherent to the
limitations of the included studies. Different outcomes were
calculated by pooling the results of a small number of
studies and patients (i.e. OPR/LBR). Moreover, a certain
heterogeneity between studies in terms of women’s charac-
teristics, timing of intervention, ovarian stimulation proto-
cols, IUI techniques and luteal phase support should be
taken into account in the interpretation of our findings.
Interpretation
Premature luteinisation and spontaneous ovulation are
considered major limiting factors for success with
IUI.25,26,29 In the present meta-analysis, we found a large
effect of GnRH-ant (introduced when the leading follicle is
about 13–14 mm in mean diameter) in the prevention of
premature luteinisation (OR 4.95, 95% CI 3.12–7.87). Nev-
ertheless, such an effect was not correlated with any advan-
tage in terms of OPR/LBR and CPR, in line with the
results of the study with the greatest weight4 (according to
the authors’ quality judgement). We may speculate but it is
still not clear how much earlier, before ovulation triggering,
the occurrence of LH increase can significantly affect IUI
success (in terms of OPR/LBR and CPR).
Interestingly, we also found that GnRH-ant administra-
tion was correlated with lower risk of cycle cancellation
due to spontaneous ovulation (OR 2.40, 95% CI 1.12–
5.15). However, among ten studies (including 2398 IUI
cycles, of which 236 were cancelled), only 36 cycles were
interrupted due to spontaneous ovulation. Therefore,
Table 1. Evidence profile: gonadotrophin-releasing hormone antagonists compared with no pituitary block in women undergoing intrauterine
insemination cycles
Patient or population: intrauterine insemination (IUI)
Setting: not applicable
Intervention: gonadotrophin-releasing hormone (GnRH) antagonists
Comparison: no pituitary block
Outcomes Anticipated absolute effectsa(95% CI) Relative
effect (95% CI)
№ of participants
(studies)
Certainty of the
evidence (GRADE)b
Comments
Risk with no pituitary
desensitisation
Risk with GnRH
antagonists
Ongoing pregnancy
rate/Live birth rate
(OPR/LBR)
140 per 1000 156 per 1000
(117–203)
OR 1.14
(0.82–1.57)
1964
(7 RCTs)
⨁⨁ss
Lowc,d
Clinical pregnancy
rate (CPR)
138 per 1.000 170 per 1.000
(135–213)
OR 1.28
(0.97–1.69)
3192
(14 RCTs)
⨁⨁ss
Lowd,e
aThe risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the
intervention (and its 95% CI).
bGRADE Working Group grades of evidence: High certainty (⨁⨁⨁⨁), we are very confident that the true effect lies close to that of the estimate
of the effect; Moderate certainty (⨁⨁⨁s), we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate
of the effect, but there is a possibility that it is substantially different; Low certainty (⨁⨁ss), our confidence in the effect estimate is limited:; the
true effect may be substantially different from the estimate of the effect; Very low certainty (⨁sss), we have very little confidence in the effect
estimate; the true effect is likely to be substantially different from the estimate of effect.
cModerate inconsistency (I2 = 39%).
dSmall number of events per group.
eModerate inconsistency (I2 = 42%).
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basing on such data and given the considerable costs of
GnRH-ant therapy (in Italy: cetrorelix 0.25 mg costs
€56.41; ganirelix coses €63.40), this strategy does not
appear to be cost-effective for the prevention of sponta-
neous ovulation in IUI cycles.
Conclusions
In summary, GnRH-ant use did not improve OPR/LBR and
CPR in women undergoing IUI stimulated cycles. Given the
benefits of GnRH-ant in reducing the risk of premature
luteinisation and spontaneous ovulation, further large and
well-designed placebo-controlled RCTs are needed.
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